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Abstract:  Technological advances and increasingly cost-effect methodologies in DNA 
sequencing and computational analysis are providing genome and proteome data for human 
adenovirus research. Applying these tools, data and derived knowledge to the development 
of vaccines against these pathogens will provide effective prophylactics. The same data and 
approaches can be applied to vector development for gene delivery in gene therapy and 
vaccine delivery protocols. Examination of several field strain genomes and their analyses 
provide examples of data that are available using these approaches. An example of the 
development of HAdV-B3 both as a vaccine and also as a vector is presented. 
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1. Introduction 
Recombinant DNA technology has provided a molecular medicine scenario and opportunity where 
a disease or illness may be treated or prevented by the introduction of a specific gene or a fragment of 
a gene into the patient using a recombinant vector. This may be either as gene therapy, where a 
missing or non-functional gene is substituted with a functional version, or as vaccination, where a 
specific defined antigen is introduced [1,2]. Adenoviruses (AdVs) have been and are currently used as 
the basis for vectors delivering these genes [1-4], despite concerns of pre-existing immune responses 
[5,6]. In the way of understanding and perhaps avoiding these problems, a confluence of genomics and 
bioinformatics approaches is useful by providing the primary DNA sequence data and analyses of the 
original genomes from which the vectors are derived, allowing for a better understanding of the 
“starting material”- the genome- and its “expression”- the virus. These data also provide detailed 
relationships of the genes found within the genomes, as well as how these gene products may relate, 
computationally, to the antigens that may have been presented in the past, through HAdV infections, 
i.e., the problem of pre-existing AdV immunity [5-7].  
A contrasting, but related and also important, topic is the development of human adenovirus 
(HAdV) genomes and viruses as a vaccine against HAdV infections [8-10]. Epidemics are caused by 
the respiratory and ocular HAdVs, especially in large, concentrated and vulnerable, i.e., unvaccinated, 
populations [11-17]. With their resulting high morbidity and occasional mortality, this preventable 
public health problem is amenable to a vaccine, similar to ones already produced, validated and 
deployed previously in the U.S. military basic trainee population [8-10,18]. The same concerns and 
‘mechanical problems’ affecting the development, safety and wide-spread applications of these HAdV 
vaccines, which are based on the use of the genomes themselves as both vector and antigen, allow 
lessons learned, using genomics and bioinformatics, to be transferred to their applications as gene 
delivery vectors in gene therapy and in vaccine therapy. Hence, the HAdV genomes themselves will be 
the focus and context of this survey of the genomics and bioinformatics resources, which provide an 
information-laden basis for the rational design of HAdV vaccines and vectors for gene delivery. 
There are two contrasting observations of the pathoepidemiology of these viruses that have 
important implications for both vaccine development and in its use as a gene delivery vector. First, 
HAdV is a pathogen that causes a range of human illnesses, including respiratory, ocular, 
gastrointestinal and metabolic diseases [19,13]; however, they may also infect aymptomatically [13]. 
Species C outbreaks have been reported as latent infections [20], which again may lead concerns of 
seroprevalence. This presents problems of pre-existing immune responses and the pathogenicity itself. 
Additionally, as the specific symptoms and illnesses are reflections of the particular organ or tissue 
infected, gene delivery roles are limited to the cell tropism of the particular HAdV. 
Second, genome stability is an important consideration. Recently, there are two contrasting 
observations of genome stability that have been presented, at the genome sequence resolution level, for 
five recent field isolates (manuscripts under review or in press) and three emergent pathogens 
[14,21,22]. Coupled with the literature that multiple simultaneous HAdV coinfections have been 
reported as inseparable mixtures [23] and documented using molecular typing methods [24-27], 
concerns of possible genome transfer between the coninfectants, perhaps resulting in new strains and 
serotypes [23], are raised. These new strains may arise as recombinants, particularly under conditions Viruses 2010, 2 
     
3
that may be ideal, such as an immunocompromised individual [23,19,28]. Recombination has been 
suggested as a pathway for new serotypes [29]; and in general, recombination is reported for HAdV 
under different conditions [30-33]. This phenomenon has been taken advantage of in constructing 
vectors [34,35]. As an infectious disease pathogen, putative recombinants are reported as “intertypic” 
and “intermediate” [36-40], with epitopes mapped by serum neutralization and/or molecular typing 
methods. These techniques are limited and allow only a partial analysis. Recent whole genome and 
bioinformatic analyses document several recombinants as highly contagious emergent pathogens 
[38,14,41,21,22,17]. These observations suggest that, perhaps at a very low rate, recombination should 
be a consideration for the safety and efficacy of HAdV vaccines and use as vectors. 
This is, and should be, balanced by a survey of several field strains which, along with their 
prototype genomes and other similar isolates, suggest that HAdV genomes may be stable in general, 
and, in one case of HAdV-C5, remarkably stable with four base changes across fifty years circulation 
both in the population and in a laboratory context (manuscript submitted). 
1.1. Synopsis of HAdV biology 
Adenoviruses are double-stranded DNA viruses that infect all vertebrates spanning fish to snakes to 
birds to humans [42,43]. Three recent reviews survey HAdVs as human pathogens, viruses and a 
“basic biology model subject” [19,13,44], so the reader is referred to these excellent sources for further 
detailed information. In brief, although their ca. 35,000-nucleotide genomes are relatively similar, 
there are many sequence differences (for example, species A is 58% identical to species C) along with 
differences in the proteomes encoded that are reflected by differences in their individual biology. 
These account for their tissue tropism, virulence, pathogenicity, host response/immune systems 
evasion and other biological characteristics. HAdVs are partitioned into seven “species” A-G, with 
species B separated into subspecies B1 and B2. Species G is recently recognized with the identification 
and description of a novel type 52 that differs from previously characterized and defined HAdVs, 
using genomics and computational methods [45]. Fifty-one serotypes based on serum neutralization 
and molecular typing techniques [23,13], were recognized until HAdV-G52 [19,13,44,45]. With, and 
based on, the genomic and bioinformatic analyses of several emergent HAdV pathogens from recent 
ocular and respiratory outbreaks, there are now 55 types reported in the literature [14,21,22]. As an 
aside, at the recent 9th International Adenovirus Meeting held in Dobogókő, Hungary (April 2009) 
where some of these genomic and bioinformatic data were presented, along with descriptions of two of 
the novel types, a formal “open floor” discussion led to a consensus of using “type” as part of the 
HAdV nomenclature scheme, allowing genome data to differentiate HAdV and keeping the original 
serotype names for 1-51. This has been touched upon in the literature earlier with opposing viewpoints 
[46]. As will be reported, and as suggested by a subcommittee at the meeting, genome data and 
computational analyses support and reconfirm the existing “serotype” nomenclature and classification 
in the context of the proposed “type” classification and nomenclature (manuscript in preparation). 
1.2. Early genomics of HAdV 
Despite the early recognition of the importance of HAdV as an infectious disease pathogen [19,13], 
its continued role as a globally circulating pathogen [13-15,38,26,17] and its previous role as a model Viruses 2010, 2 
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“organism” in DNA replication biochemistry, cell and molecular biology [44], HAdV genomes and 
their analyses have lagged behind other genomes in the genomics era until recently. As DNA 
sequencing technologies have improved and as the focus of DNA sequencing targets shifted from 
smaller “feasible” genomes, e.g., Phi-X174 and mitochondrion, to the larger, e.g., H. influenza and E. 
coli, and then to the much larger, “more relevant” (to human health and well-being) and “sexier and 
exotic” genomes, e.g., human, rice, silkworm and panda, adenoviruses were left behind. These 
thoughts do “not hold water” as adenoviruses have a tremendous impact on human biology both as a 
pathogen and as a biotechnology tool! As of 2002, there were only five HAdV genomes archived in 
GenBank, consisting of genomes that were “cobbled together” as composites of earlier published data 
that were coupled with “final pieces” sequenced to put together a complete genome. The original 
sequences, deposited by different researchers, were obtained using different sequencing methodologies 
and using, likely, in-house laboratory-circulating version of the prototypes. These include genomes for 
HAdV-C2 [47], HAdV-C5 [48], HAdV-A12 [49], HAdV-D17 (Genzyme Corp.; GenBank 1998) and 
HAdV-F40 [50]. With the exception of HAdV-D17, having documented sequencing errors [43], these 
genomes are still useful as reference sequences and relevant to understanding HAdV biology and 
evolution, especially with the continued annotation of their genomes [43] and the recent high 
resolution descriptions of recombination events in HAdV genomes [41,51,21,22]. The importance of 
the HAdV-C5 genome is demonstrated in the resequencing of its genome using a single methodology, 
and by the preparation, designation and distribution of an industry standard, “Adenovirus Reference 
Material” (ARM), available from ATCC (Manassas, VA) [52]. 
1.3. Current genomics of HAdV 
In contrast to the “tsunami” of genome sequences generated for bacteriophage, viral, mitochondrial, 
bacterial and eukaryotic genomes paralleling the rapid and continued development of faster, robust, 
more efficient and more cost-effective DNA sequencing technologies and its application to many 
organisms and groups of organisms, the HAdV genomes database had been sparsely populated. Given 
the increasing and improving number of genomic and bioinformatic tools and methods, it seemed 
sensible to examine the well-studied AdVs using these approaches. In particular, one application is in 
biotechnological applications including vaccine development and diagnostics platforms. Apparently 
this was of interest to several research groups as well, as a “seiche” (rather than a tsunami) of HAdV 
sequences appeared. HAdV-B35 was sequenced independently by two different groups, both interested 
in vector development and the use of HAdV-B35 as an alternative to HAdV-C5 in gene therapy and 
gene transfer applications [53,7], and, in part, to bypass pre-existing HAdV-C immunity. The HAdV-
B11 genome was sequenced independently twice at this time as well [54,55]. In addition, the first 
HAdV to be described clinically and historically was also sequenced in this time period, as a prelude to 
sequencing and analyzing the rest of the prototypes and several field strains responsible for respiratory 
diseases, especially acute respiratory disease (ARD) [56]. A practical consideration for these genomes 
was for the identification of sequence diagnostic probes for the development of a microarray-based 
surveillance and diagnostics assay [25]. Subsequently, the release into GenBank of 16 additional 
genome data sets from the authors, HAdV-B3 (two genomes), HAdV-B7 (three genomes), HAdV-
B16, HAdV-B21, HAdV-B50, HAdV-B14, HAdV-B34, HAdV-C5, HAdV-C6 (embargoed) and 
HAdV-E4 (four genomes), added to the growing number of available HAdV genomes [25,56-60]. Also Viruses 2010, 2 
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available were five chimpanzee AdV genomes [61,62], which are of interest as alternative gene 
delivery vectors. Currently, there are 31 prototype and 37 field isolate genomes deposited in GenBank, 
with the number expected to grow as clinical investigations of HAdV-associated illnesses are leading 
to the identification of putatively interesting HAdVs. One such interesting observation involved a 
recent fatal case of ARD, with an identified HAdV isolate that also was a highly contagious ocular 
pathogen [63]. 
2. Tools and methodologies of bioinformatics for adenovirus genomes 
2.1. Genomics: acquisition of data 
The advent of genomics and bioinformatics has complemented and extended the available data and 
tools for characterizing and developing vaccines, as well as for vector development in gene transfer 
and delivery based on HAdVs. Having in hand the exact nucleotide sequence allows more precise and 
defined manipulation of the genome. Knowing exactly where and how much of the original genome to 
delete to allow the insertion of expressible heterologous sequences and having rapid access to the set 
of in silico proteome allows comparisons across similar genomes to ascertain critical and 
“unimportant” genes, and allows non-essential genes to be deleted. Limited resequencing ensures no 
genome and gene insert changes are inadvertently in the final product. Finally, as cell tropism is 
embedded in the primary sequence and plays a role in the delivery of genes to targeted cell types [64-
66], it may be possible to alter tropism. 
Sanger-based dideoxy-sequencing chemistry has been the standard methodology to date. Its several 
variations, conveniently and uniformly converted into kit formats, allow for high-throughput 
automation; for example, DYEnamic ET Terminator Cycle Sequencing kits (Amersham Biosciences; 
Piscataway, NJ, USA) generated ladders that were resolved on an ABI Prism 377 Sequencer (Applied 
Biosystems; Foster City, CA, USA), and were the basis for the genomes sequenced by the authors. The 
development and application of “Next Generation” instrumentation and protocols are creating 
opportunities to obtain much greater numbers of HAdV genomes, allowing for detailed examinations 
of HAdV, including pathoepidemiology and molecular evolution. Given the number and flux of new 
technologies, and the lack of use with these systems in AdV genomic studies, we will not discuss their 
use here. It is noted that each technology has its own particular strengths and weaknesses, and these 
will need to be understood with regards to AdV genomics. 
In general, regardless of the technology, there are two common considerations for HAdV genome 
sequencing. One is accuracy and quality control. For the Sanger-based method, a minimum three-fold 
coverage across the entire genome is required, with problematic regions and potentially relevant SNPs 
to be covered by additional re-sequencing. A “2+1” strategy, that of obtaining sequences comprising 
both strands, allows high confidence in the genome data. Another method to ensure high quality 
sequence data is to analyze the proteome with computational means. For all sequencing methods, 
sequence assembly, particularly from “short read” ladders of some protocols, and the quality control of 
these genome sequences may be augmented by the annotation process. In other words, there are 
essential genes, such as hexon, penton, fiber, and genome features, such as the inverted terminal 
repeats (ITRs), that must be present and within a certain conserved range of sequences. Having an Viruses 2010, 2 
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annotation allows unreliable data to be re-sequenced for resolution, allowing a ten-fold increase in 
sequence accuracy. 
Second, there are regions that may be difficult to sequence, given a particular technology. One 
example for the Sanger methodology is the ends of the AdV genome. Both ends of this linear HAdV 
molecule contain inverted terminal repeats (ITRs). These should complement each other, and serve as 
a quality control check. One end may be sequenced by DNA polymerase “running off the template”; 
the other end is problematic, as DNA polymerase requires a template to initiate. An additional 
complication is that HAdV genomes contain a covalently linked protein that is attached to the end. 
One solution to circumvent these obstacles is to use a “rapid amplification of cDNA ends” kit (5’/3’ 
RACE; Roche Diagnostics Corp.), with modifications [22].  
2.2. Bioinformatics 
2.2.1. Genome analysis 
Computational analyses of the genome involve examining the nucleotide sequence of the genome 
and the protein sequences of the proteome. There are many software tools available, both as 
commercial packages and as public resources on the Internet. One site housing the URLs for many 
public resource software tools is http://molbiol-tools.ca/. Specific tools used in our studies are 
described here and detailed in Table 1. 
For DNA sequencing ladders assembly, DNA Sequencher (Gene Codes Corp.; Ann Arbor, MI, 
USA) was used for the completion of the seventeen genomes noted earlier as submitted by the authors. 
This software can also be used to align sequences and, importantly, manually move them, allowing 
visual characterization of recombinant or deleted sequences. 
As noted above, once a consensus contig genome is produced, a quick examination of certain 
“landmarks” is useful, for example, the ITRs, pTP and Pol genes are difficult to sequence. A first pass 
annotation, to be described later, is recommended as a sequence quality control step before additional 
effort and excitement are expended, or as admonished by a biochemist as one of the “Ten 
commandments of enzymology”: “Don’t waste clean thinking on dirty enzyme” [67]. 
The attributes of the genome include GC content, with the percent GC diagnostic of species: A 
(47%), B1 (51%), B2 (49%), C (55%), D (57%), E (57%), F (51%) and G (55%). Genome lengths are 
not indicative of species and range from 34,125 bases (HAdV-A12) to 36,015 (HAdV-E4). The 
percent identity of a new genome may be determined relative to sequenced genomes; for example, 
species A is 58% identical to species C. The genome nucleotide sequence can be examined for repeats 
using PipMaker. This software uses a BlastZ algorithm to compute the local alignments of pairs of 
genomes and produces dot plots that give an indication of the similarity of the two genomes, as well as 
highlights any genome rearrangements [68]; the highest similarity scoring fragments will align on a 
diagonal. On the same site, zPicture gives another version of this genome identity analysis. 
Multiple whole genome alignments, of genomes the size of HAdV, can be made using MAVID 
(http://baboon.math.berkeley.edu/mavid) [69]. MAVID, in turn, produces alignment outputs that may 
be ported into phylogeny tree analysis algorithm. For our studies, neighbor-joining trees [70] are 
constructed using MEGA4 [71]. Genome recombination events can be found in the genome 
alignments. Recombination is a contributing factor in the evolution of HAdV [14,51,21,22], as noted Viruses 2010, 2 
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for driving serotype evolution based on serum neutralization studies [29]. Sequence recombination can 
be detected whole and partial genome alignments, using Bootscan and SimPlot [72], with other 
comparable software also available [73]. 
Although seemingly anachronistic, restriction enzyme (RE) pattern analysis is still very useful, 
particularly to understand the context of the genomes relative to previously reported RE patterns of 
isolates reported in the literature. It should also be noted that as a “whole genome scan” tool, i.e., a 
“genotyping” tool, RE patterns are effective for a rapid visual overview and comparison of the 
nucleotide genomes. The pDRAW32 software is one example for this in silico RE analysis. Also, the 
availability of genome data allows unlimited RE patterns and resolution of “faint” and multiple bands, 
and allows much better resolution than gel-based and photograph-based gel data in the literature. 
2.2.2. Proteome analysis 
A full-length annotation of coding and non-coding sequences completes the presentation of the 
genome sequence and extraction of information from the nucleotide string. In the past, HAdV and 
simian adenovirus (SAdV) sequences deposited in GenBank were incompletely annotated, with only a 
minimal annotation associated, particularly if submitted for patent purposes. We have developed a beta 
version of an automated genome annotator for our studies. This gives a “first pass” annotation that is 
suitable for assessing sequencing data quality. Refinement of the annotation manually as well as the 
examination of genome differences can be done using a genome viewer such as Artemis [74]. 
The proteome may be examined computationally, using percent identity comparisons of the 
nucleotide sequence and the amino acid percent identities of the proteins. These are manually 
calculated using the EMBOSS package [75]; more recently a beta version of an automated tool allows 
the same calculations. This provides an independent view to any recombination events. 
Individual proteins and genome landmarks, e.g., ITRs, may be analyzed phylogenetically, using 
CLUSTAL for multiple sequence alignments (MSA) [76] and porting into phylogeny tree analysis 
software. One example of the relevance of this approach is a report showing the zoonotic origin of 
HAdV-E4 from chimpanzees [57]. An implication of the proteome analysis is a suggestion that the use 
of chimpanzee AdVs as alternatives in gene delivery in order to bypass pre-existing immune response 
may not be advisable, or should be done with caution. 
2.2.3. Informatics support 
The Internet provides opportunities for worldwide interactions and collaborations, and for 
community-based resources. An “AdenovirusWiki” has been developed as an open resource for 
adenovirus research. In addition to the software tools available on the Internet, several local tools are 
also available, as beta versions: automated genome annotation; proteome percent identity analysis; and 
gene mapping tool (Figure 1); (www.irgolf.com/genemapv2). These provide for a pipeline to take a 
genome nucleotide sequence through analyses to produce genome annotations, proteome identification 
and analyses and a presentation of the coding sequences on a genome schematic. 
A local tool developed in the authors’ research group is “Virus Genome Annotation Tool” (VGAT). 
This is a beta version that is publicly available, with the caveat that it is a test version, at 
http://binf.gmu.edu/zenith/tool/lghmms.php. VGAT uses “Hidden Markov Models” (HMMs) to Viruses 2010, 2 
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annotate virus genomes. Currently, this software tool has been trained to annotate members of the 
HAdV-D species. It can be expanded to include members of other HAdV species, and the ability to 
add user defined training sets will be added. 
A tool for automatically comparing the protein percent similarities in proteomes relative to their 
homologs in other proteomes is available in a beta form. The protein alignments and percent identities 
are calculated using a BioJava implementation [77] of a Needleman and Wunsch algorithm. When 
completed, the tool will be publicly available via the Internet; currently this tool is available upon 
request.  
Figure 1. Automated gene-mapping tool. A field strain of HAdV-B7 (accession number 
AY601635; strain designation #NHRC 7151) has been sequenced and annotated. Its coding 
sequences are displayed using a gene-mapping tool using a derived annotation table. 
 
 
2.2.4. Bioinformatics Tools Summary 
Again, all of the computational tools noted for our studies are summarized in Table 1. As mentioned 
in the text, two are beta versions and need to be optimized. There are additional and equivalent 
software tools available over the internet, including multiple independent tools for similar analyses. A 
caveat is that some may be limited to certain computer platforms and need to be compiled. In some 
cases, the original contributors may no longer support some tools (orphans); however, some tools may 
be very useful and still supported, albeit at a different URL due to the contributor changing physical 
addresses. These may be found by ‘googling’ the tool name and/or the author on the Internet to locate 
the tool. 
Table 1. Summary of Bioinformatics Tools. 
Tool Purpose  Availability 
Sequencher sequence  assembly  Commercial 
PipMaker  genome sequence analysis  http://pipmaker.bx.psu.edu/cgi-bin/pipmaker?basic 
zPicture  genome sequence analysis  http://zpicture.dcode.org 
MAVID whole  genome  alignment  http://baboon.math.berkeley.edu/mavid Viruses 2010, 2 
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Table 1. Cont. 
MEGA4 alignment  viewer,  phylogeny http://www.megasoftware.net/ 
Simplot recombination  analysis  http://sray.med.som.jhmi.edu/SCRoftware/simplot/ 
pDRAW32  in silico restriction enzyme digest http://www.acaclone.com/ 
Artemis  sequence viewer, annotation tool http://www.sanger.ac.uk/Software/Artemis/ 
EMBOSS sequence  analysis  http://emboss.sourceforge.net/ 
Auto % Id beta  sequence % id  available upon request 
Clustal sequence  alignment  http://www.clustal.org/ 
Adenovirus Wiki  repository of adenovirus data http://www.binf.gmu.edu/wiki/index.php/Main_Page 
Mapping Tool beta  create gene maps  www.irgolf.com/genemapv2 
VGAT beta  automated virus genome annotation  http://binf.gmu.edu/zenith/tool/lghmms.php 
 
3. Considerations of HAdVs for vaccine development and for vectors development for gene 
transfer and delivery 
Limited molecular typing, e.g., PCR amplification coupled with DNA sequencing of certain targets, 
is a quick informative method to be applied in rationally designing adenoviral gene delivery vectors 
and in screening HAdVs and constructs as vector candidates [78-80]. Molecularly typing the outer coat 
proteins, hexon, penton and fiber, is important as they have critical roles in tissue tropism as well as in 
the host immune response to the virus. A caveat is that genome recombination may occur at other 
locations that may have subsequent and important consequences in the biotechnological application of 
the genome. 
Although HAdV species C was initially the focus as vectors for biomedical and biotechnological 
applications, current interest range beyond this group. There have been many vectors based on other 
human, and even non-human, AdV serotypes that have developed as vectors for gene delivery and 
vaccine development. One review by Stone et al. [81] is an example. Primary literature citations 
include [2,4,7,53,62,82-89]. It is anticipated that genomics and bioinformatics resources will aid in 
these on-going work and development. 
3.1. Natural variation of HAdV genomes 
As noted earlier, recombination events are hallmarks of HAdV in vitro, and have now been 
documented in whole genome studies. The rate of recombination is not yet known. It may be that some 
species or types may be amenable to recombination based on sequence, e.g., hotspots, and biology, 
e.g., cell tropism and coinfection. Mutations as nucleotide changes, such as insertions and deletions 
(indels) and substitutions, are more common. However, given the fidelity of the DNA polymerase, the 
relevance of these genome changes remains to be elucidated. The question relevant to both HAdV 
vaccine development and gene delivery vector design is: How stable are these genomes? 
Genomes from some isolates appear to be very stable, at least from the viewpoint of their antigenic 
epitopes. For example, the HAdV-B7 and E4 vaccines were highly effective in the U.S. military basic 
trainee population [8-10,18] for over twenty-five years [9]. This suggests, at least, a conservation of 
the epitopes for these two serotypes. A genome comparison of the prototype versus the “vaccine” 
(presumably the “then-circulating” and dominant) strains of both HAdV-B7 and HAdV-E4 showed Viruses 2010, 2 
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few genome changes, mainly indels and base substitutions [57-59]. These strains were of the 1950s 
and 1960s era. A pair of more recent HAdV-E4 field strains (accession number AY599837; strain 
designation #NHRC 3) and (AY599835; NHRC 42606), from two different outbreaks, and a recent 
HAdV-B7 field strain (AY601634; NHRC 1315) were sequenced, as 1990s isolates, to allow a 
comparison of their genomes. These showed similar limited mutations as well. Figure 2 displays whole 
genome comparisons of the three HAdV-B7 strains, across approximately forty-five years. Based on 
these whole genomes analyses and based on molecular typing, e.g., PCR amplification coupled with 
sequencing, of critical epitopes, it is likely the vaccines in production will be effective, as these 
genomes appear relatively stable.  
Figure 2. HAdV-B7 genome comparisons. Three HAdV-B7 genomes, spanning ca. 1950s 
to 1990s, are analyzed using zPicture. Locations of the outer coat proteins, which are 
critical putative epitopes and cell tropism determinants, are arrayed for reference.  
 
 
Proteome analysis allowed a detailed examination of all three HAdV-B7 genomes. Table 2 shows 
that despite the nucleotide differences, the protein percent identities are high, with the exception of the 
agnoprotein and the E3 7.7 kDa protein. The E3 difference may be important as those proteins may 
have roles in host immune response [90].  
Similar genome and proteome data were obtained from analyses with HAdV-E4p, HAdV-E4_vac, 
HAdV-E4_FS1 and HAdV-E4_FS2 (data not shown). Two other prototype (ca. 1960s) and field strain 
(ca. 1990s) genomes have been paired and sequenced (or extracted from GenBank) as well: HAdV-B3 
and HAdV-B3_FS (AY599836; NHRC 1276); and HAdV-C5 and HAdV-C5_FS (AY601635; NHRC 
7151). Additionally, the HAdV-B3 genomes were compared with two field strains sequenced and 
described in China as well as a laboratory-circulating strain [91]. Genomes available for the HAdV-C5 
analysis are even more interesting, as two prototype genomes were available from GenBank: 1) the 
original report, a composite presumably of several laboratory-circulating strains; and 2) an 
amplification of the original prototype from ATCC (Manassas, VA, USA) and now available as an 
“Adenovirus Reference Material” (ARM). Shown in Figure 3, these versions of the prototype were 
compared to the genome of a field strain, HAdV-C5_FS, which was isolated as one of a pair of Viruses 2010, 2 
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coinfecting HAdVs (manuscript submitted). The other coinfectant was HAdV-B21 and no signs of 
recombination in the HAdV-C5 genome were observed. Only four genome changes (one substitution 
and three indels) separated the 1998 field strain from the 1953 prototype (ARM). HAdV-C5_FS differs 
slightly more from the circulating laboratory strain (99.9%), suggesting laboratory passages allow 
some unselected mutations to accumulate. 
Table 2. Proteome Analysis of HAdV-B7. Percent identities of proteins amongst the 
reported three genomes of HAdV-B7 are calculated, relative to the HAdV-B7_FS 
proteome. 
HAdV-B7_FS HAdV-B7_vac  HAdV-B7p 
E1A 28 kDa protein  98.9  99.6 
E1A 32 kDa protein  98.3  99.6 
E1A 6 kDa protein  98.3  100.0 
E1B 20 kDa protein  100.0  98.3 
E1B 55 kDa protein  100.0  99.0 
IX protein  100.0  100.0 
IVa2 protein  99.3  98.9 
DNA polymerase      99.7  98.2 
Hypothetical 99.1 98.1 
agnoprotein 99.5  72.7 
Hypothetical 100.0  68.4 
Terminal protein  100.0  98.8 
Hypothetical 99.2 95.5 
Hypothetical 98.9 93.4 
52 kDa protein  99.2  97.4 
IIIa protein  99.1  99.7 
penton base protein   98.7  99.3 
VII protein  98.4  99.5 
V protein  98.3  98.3 
X protein  98.3  98.3 
VI protein  96.4  96.8 
hexon 99.8  97.0 
protease 100.0  97.6 
DBP 99.8  97.7 
100 kDa protein  99.6  98.2 
33 kDa protein  98.3  83.9 
22 kDa protein  100.0  97.5 
VIII protein  86.8  86.3 
E3 12.1 kDa  100.0  100.0 
E3 CR1-α 100.0  99.3 
E3 glycoprotein  100.0  100.0 
E3 CR1-β 95.5  93.3 
E3 CR1-γ 99.5  98.4 
E3 7.7 kDa protein  100.0  59.1 
E3 RID-α 100.0  100.0 
E3 RID-β 92.4  100.0 
E3 14.7 kDa protein  100.0  99.3 
U protein  100.0  98.1 
fiber 99.7  98.8 
E4 ORF 6/7 protein  100.0  100.0 
E4 32 kDa protein  99.3  98.7 
E4 ORF 4 protein   98.4  95.9 Viruses 2010, 2 
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Table 2. Cont. 
agnoprotein 99.4  97.0 
E4 ORF 3 protein  99.1  99.1 
E4 ORF 2 protein  96.9  98.4 
E4 ORF 1 protein   98.4  96.0 
 
Figure 3. HAdV-C5 genome comparison with zPicture. Genomes of a laboratory-
circulating strain and a coinfectant field strain of HAdV-C5 are compared with the 
reference prototype (ARM). The field strain genome has ~100% sequence identity with the 
ARM strain, with four nucleotide differences across 45 years. 
 
 
The apparent stability of these examples suggests that, in some cases, HAdV genomes are not as 
vulnerable to large-scale genome changes, such as recombination events. Accumulation of indels and 
base substitutions do occur, as would be expected, although in one case, HAdV-C5, it can be 
surprisingly few in number. All of these observations, including the highly effective nature of the 
HAdV-B7 and E4 vaccines earlier, imply that vaccines developed and vectors developed using HAdV 
genomes may be stable and useful for a period of time.  
3.2. Natural variation of HAdV genomes: new types, new species, and vector candidate 
Novel HAdV may be candidates in the quest for effective, appropriate (e.g., tissue and organ 
specific) and safe (e.g., asymptomatic and non-immunogenic) vectors. Genomics and bioinformatics 
have provided the identification and characterization of HADV-52, isolated from the stool of a patient 
with gastroenteritis [45]. As it was distinguished on the basis of genomics and bioinformatics rather 
than the traditional immunochemical techniques, it is referred to as “type” rather than the inappropriate 
“serotype”. In addition, the case has been made for it as both a new type and a new species as well; the 
opposing view has been discussed in the literature [46]. There are additional computational data, 
derived from bioinformatic methods noted earlier, that were not reported in the original report which Viruses 2010, 2 
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provide strong support for this as well. HAdV-G52 shows a very high whole genome percent 
nucleotide identity with SAdV-G1, a simian (monkey) AdV, at 95.5%. This has been proposed as a 
member of species G. In contrast, the percent identity with SAdV-G7 is also high at 82.9%, another 
proposed species G member. The percent identities between the next phylogenetically closest, and also 
gastrointestinal, viruses HAdV-F40 and HAdV-F41 are much lower at approximately 69%. For 
reference, the percent identity between HAdV-F40 and HAdV-F41 is 85.8%, both members of species 
F. GC analysis shows a clustering of HAdV-G52 (55.1%), SAdV-G1 (55.2%) and SAdV-G7 (56.3%) 
as opposed to HAdV-F40 (51.2%) and HAdV-F41 (51.0%); again, GC contents seem to correlate with 
species grouping when surveyed across all of the sequenced genomes (data not shown). 
Moreover, whole genome phylogenetic analysis (Figure 4) shows that HAdV-G52 subclades with 
SAdV-G1 and SAdV-G7. HAdV-F40 and HAdV-F41 forms a separate subclade. Proteome analysis, in 
the form of percent similarities, also shows closer relationships between the proposed “G” species 
members than with the other HAdV (data shown in Table 3). HAdV-G52 is missing the RL3 protein, 
which is unique to HAdV-F proteomes; this is also not in genomes of the other available genomes 
including the two simian ones grouped as species G. The RL3 protein is a 6.7 kDa protein that is 
encoded by E3 [92]. The function of RL3 is thought to be in directing glycoproteins to the 
endoplasmic reticulum [92]. 
Figure 4. Whole genome phylogenetic tree. HAdV-G52 subclades with SAdV-G1 and 
SAdV-G7. HAdV-F40 and HAdV-F41 subclade separately. Numbers presented are percent 
bootstrap replicates. 
 
 
These results, taken with the original data, strongly suggest that HAdV-G52 is more related to 
SAdV-G1 and SAdV-G7 than to HAdV-F40 and HAdV-F41, and sufficiently different to merit 
designation as a new type and species. It would be inappropriate to refer to this strain as a “serotype” 
HAdV-G52 as no comprehensive serotyping data were provided to distinguish it from the accepted Viruses 2010, 2 
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ones; however, it is clearly different from the 52 established serotypes. These data also suggest the two 
monkey AdVs are likely members of species G and may suggest a zoonotic origin for HAdV-G52. 
Given the lower percent identity scores with the other HAdVs (data not shown), HAdV-G52 may be a 
strong candidate as a vector for gene delivery, possibly avoiding pre-existing immunity issues. 
Table 3. Protein percent identities of species F and G, relative to HAdV-G52. To assess 
the relationships between proteomes of species G and F, protein percent identities were 
calculated. One, denoted as “*” was not found in HAdV-G52. 
 
 
Adenovirus 
Percent Identity, relative to HAdV-G52  
E1A 
E1B 
55 
kDa 
protein 
IVa2 
DNA 
Pol 
pTP 
L1 55 
kDa 
protein 
L2 
penton 
L3 
hexon 
E2A 
DBP 
CR1-
alpha1 
(RL1) 
CR1-
beta1 
(RL2) 
RL3* 
L5 
fiber1 
L5 
fiber2 
E4 
34 
kDa 
SAdV-G1 92.3 99.2 99.1  98.6  99.5 100  99.2 92.3  94.6  97.7 97.0  -  82.6 98.6  100 
SAdV-G7 38.6 90.3 98.9  97.6  98.8 99.7  93.3 90.0  94.8  -  -  -  59.3 72.1  98.3 
HAdV-F40 47.1  68.2  87.7 78.5 82.4  82.6  86.1 84.7  62.3  44.3 35.7  +  37.8 52.7  62.3 
HAdV-F41 42.8  68.5  89.5 79.9 84.4  83.8  87.1 87.8  66.1  44.3 34.8  +  38.5 53.4  61.2 
 
3.3. Natural variation of AdV genomes: non-human primate AdV genomics and vector candidates 
The persistence, infectivity and wide distribution of HAdV in general lead to concerns of pre-
existing immunity, as characterized by seroprevalence [7]. This, in turn, leads to concerns with the use 
of HAdV as vectors. In an attempt to develop vectors that may be free of potential problems, 
alternative non-human AdVs may be appropriate substitutes as vector candidates, especially those 
from the great apes which presumably can infect human cells due to similarities. 
A growing number of such AdVs are beginning to be isolated, characterized and examined for use 
as vectors. A recent contribution of 33 novel non-human primate genomes (30 ape and three macaque) 
has been reported and deposited in GenBank [93]. These are in addition to several monkey AdV 
genomes, sporadically deposited as simian AdV (SAdV) since 2004, and the five original chimpanzee 
AdV genomes, also noted as SAdVs, deposited into GenBank in 2004 [61,62]. The first chimpanzee 
AdVs were originally deposited at the American Type Culture Collection (ATCC) in the 1960s-70s, so 
these 33 additional genomes represent a recent, renewed and directed interest in novel non-human 
primate AdVs. Biotechnological applications, including vector applications, appear to drive the 
enthusiasm for the collection and characterization of these genomes. At least three groups are 
contributing to this seiche of monkey and great ape AdV genomes (noted collectively in the past as 
“simian”), as per several reports at the recent 9th International Adenovirus Meeting (Dobogókő, 
Hungary; April 2009). Given the wide diversity of genomes and this larger collection, it was suggested 
then by one of authors that it may be appropriate to standardize the nomenclature, to one that is also 
discriminatory and informative. Rather than classifying them all as “simian” AdVs (SAdVs; for 
example, [93]), subclassification into chimpanzee (ChAdV; for example, [82]), bonobo (BoAdV), Viruses 2010, 2 
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gorilla (GoAdV) and perhaps monkey (MoAdV), etc. may be more appropriate, especially for eventual 
“Big Picture” analyses of all genomes and for discussions of HAdV origins, molecular evolution, 
natural histories, taxonomy and virus reservoirs. 
As a result of recent interests, the inventory of non-human primate AdV genomes is growing at a 
rapid pace, and the genomes are providing alternative biotechnology tools as well as providing 
resources for a more detailed glimpse into the biology, genomics and bioinformatics of HAdVs. The 
availability of these and other primate genomes allow more thorough computational analysis and finer 
resolutions of earlier observations. For example, discussed earlier were the zoonotic origins of HAdV-
E4 and species E from the chimpanzee [94,95,57]. The recent 33 novel non-human primate genomes 
are parsed by genome analysis into HAdV species B, C and E [93], complementing the B and E 
species partitioning of the original SAdV-21 through SAdV-25, and confirming a close phylogenetic 
relationship with the HAdVs. As the recently described AdVs were collected as samples from 
substantial and persistent shedding in the stools of asymptomatic and apparently healthy primates, a 
comment (and caution) as to a zoonosis potential was noted. Noted also was the possibility and 
observation of intraspecies recombination in one of these primate AdV genomes [93], echoing recent 
reports of genome recombination in HAdV [14,51,21]. These two possibilities, zoonosis and 
recombination, may have relevance in understanding pre-existing human seroprevalence as well, as the 
earlier computational analysis of HAdV-E4 showed protein homologies to the chimpanzee AdVs 
(SAdV-21 through SAdV-25). Further bioinformatic analyses should be applied to these new genomes. 
Chimpanzee AdVs have been developed into vectors for potential human applications recently and 
in the near past [82-84]. It is anticipated that both genomics and bioinformatics will play large roles in 
the further and continuing development and applications of these AdVs of human uses, especially 
within the context of the rational design of vectors for gene delivery. 
4. Applications 
Genomics and bioinformatics have provided a more detailed understanding and another dimension 
of these viruses through their genomes and proteomes. These are very useful in the context of vaccine 
development and also in the continuing biotechnological development of HAdV genomes as a vector 
for gene delivery. As an example, HAdV-B3 is discussed as a subject for both applications. This 
particular ARD infectious disease agent remains a global pathogen and is a public health problem, 
particularly in high-density populations [96]. Data suggest that a vaccine developed against a particular 
HAdV may be cost-effective and will be an effective prophylactic for an extended period of time, e.g., 
stable genome, similar to the original HAdV-B7 and HAdV-E4 vaccines. On the other hand, 
seroprevalence due to its circulation is a concern and limits its use as a vector [7]. 
4.1. Applications: development of HAdV-B3 vaccine 
HAdV-B3 remains an important human pathogen for ARD [13,96]. The serotype is considered 
highly virulent and has been associated with high morbidity, due to pharyngoconjunctival fever and 
residual lung damage, as well as mortality in children [97,98]. Currently there is no effective vaccine 
against HAdV-B3 infection. Therefore, it makes sense to have a safe, effective, readily available and 
inexpensive vaccine available against this virus in the countries with very dense and vulnerable Viruses 2010, 2 
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populations, especially in populations where the prevalence of HAdV-B3-specific neutralizing 
antibodies is very low. To this end, Zhang et al. have developed a replication-competent recombinant 
HAdV-B3 rAdΔE3GFP vector expressing eGFP as a vaccine candidate [85]. 
As shown in Figure 5, a recombinant virus was constructed by deleting a 3,164 nucleotide segment 
in the non-essential E3 region (nucleotides 27,737–30,900), yielding the rAdΔE3GFP genome [85]. A 
CMV-eGFP-SV40 expression cassette (1,616 nucleotides) was inserted into the E3 region by 
recombination. The left 663 bp and right 219 bp flanking E3 regions remained in place. In theory, a 
maximum size of 4,800 nucleotides (foreign gene) can be inserted into this E3-deletion vector. Mice 
immunized with the recombinant eGFP AdV by either intramuscular injection, intragastric or 
intranasal inoculation routes raised a significant antibody response to eGFP and to the wild-type 
HAdV-B3 GZ1 strain at the same time [96,85]. Alternatively, Li et al. constructed another replication-
defective HAdV-B3 by the deletion of the entire E1 region for use also as a vaccine candidate [86]. 
Wild-type HAdV-B3 can be neutralized by the sera from the mice intramuscularly immunized with 
this recombinant virus [86]. 
Figure 5. Deletion map of the E3 region in the recombinant pBRAdΔE3GFP vector. The 
red region indicates the deletion in the HAdV-B3. Blue regions indicate remaining left and 
right regions of the E3 region. Black regions indicate VIII protein and the fiber, L4 and L5 
regions respectively. The green indicates the gap between the E3 region and the L5 fiber 
region. 
 
 
In the U.S., deployment of live enteric-coated oral vaccines against HAdV-B7 and HAdV-E4 was 
successful in removing both pathogens as agents for ARD for approximately twenty-five years [99]. 
Both vaccine strains presumably and selectively infected the lower intestinal tract, as administered in Viruses 2010, 2 
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these enteric-coated capsules, and stimulated the production of appropriate neutralizing and circulating 
antibodies. No adverse signs or symptoms of illness were associated with these two vaccines [8,100]. 
Similarly, the replication-competent HAdV-B3 may act as an effective and safe vaccine candidate as 
well when administered in enteric-coated oral capsules. No helper cells are needed and the necessary 
virus titers should be easy to obtain. Additionally and importantly, this vaccine genome could be used 
either as a bivalent or trivalent vaccine for the delivery of more viral antigens. Continuing work with 
the heterologous expression of the HAdV-B7 hexon in this vector is underway [85]. 
4.2. Applications: development of HAdV-B3 as a vector for gene delivery 
Many gene therapy vectors, to date, used in human clinical applications are currently based on 
species C members: HAdV-C5 and HAdV-C2. However, the apparent pre-existing immunity against 
them, from previous infections [101,7], and the lack of the coxsackie and adenovirus receptor (CAR) 
or integrin expression in target cells may be of concern, for the safety of the patient and the efficacy of 
these species C-based AdV vectors [64,66], respectively. 
As a consequence and an attempt at rational design of vectors, species B have been explored as 
alternatives, both as to increase the range of cells infected and to bypass pre-existing immunity [53-
55,87,81,7]. For example, HAdV-B3 is reported to gain entry into cells through alternate receptors: 
CDX, CD46, CD80 or CD86 [65,102-106]. These are expressed in a multitude of cell types, including 
important gene therapy target cells that express either no or low levels of CAR. Therefore, HAdV-B3 
may be an alternative to HAdV-C5-based gene-transfer vectors. A recombinant E1-deleted HAdV-B3 
vector has been engineered on a bacterial artificial chromosome [88]. It is efficiently transduced into 
CD46-positive rodent and human cells. Another replication-defective HAdV-B3 vector was also 
constructed independently by molecular cloning [86]. These viruses were shown to replicate in an E1-
complementing cell line. Other recombinant species B-based replication-defective vectors have also 
been developed: HAdV-B7 [89], HAdV-B11 [107,87] and HAdV-B35 [53,7]. However, 
seroprevalence due to presumably previous HAdV-B3 infections may be of concern. More studies are 
still needed for the effective and appropriate safe applications of these vectors for in vivo gene transfer. 
5. Conclusions 
Taking advantage of the recent and continuing improvements in high-throughput DNA sequencing 
technology and methodology, coupled with a myriad of bioinformatic tools developed for other 
organisms and areas of research, the HAdV researchers now have a wealth of genome and proteome 
resources to apply to understanding the comprehensive and integrated biology of the virus, including 
deeper and finer points concerning viral origins, putative reservoirs, molecular evolution, natural 
histories and taxonomy. These data have been applied to the development of vectors for gene delivery, 
either for gene therapy applications or for the delivery of antigens in vaccine development. Several of 
the early genomes sequenced were done so for this purpose. Research examining the natural variation 
of HAdVs, as well as the molecular evolution of their genomes, particularly in the context of emerging 
pathogens, has shown that the genomes are seemingly stable, that is accumulating indels and base 
substitutions commonly and recombination less commonly. These observations have relevance in 
understanding the biology and the pathoepidemiology of adenoviruses as a whole, and, importantly, Viruses 2010, 2 
     
18
also have relevance in the development of vaccines against these pathogens as well as the 
biotechnological applications in vector development. 
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